Replies to post #148107 on Anavex Life Sciences Corp (AVXL)

[McMagyar]

World Orphan Drug Congress USA 2018 - Conference Day One @ 11:25
Empowered educated patients influencing pre-clinical development and working with industry to optimize drug discovery
Patient groups role guiding research, disease understanding, supporting pre-clinical development and follow up experiments
Driving translational research and the influence on formulation, routes to delivery and overall clinical development
Effective partnerships between advocacy and industry to expand collaborations that can support enrollment and physician engagement
Christopher Missling, President and CEO, Anavex Life Sciences
Steven Kaminsky, Chief Science Officer, International Rett Syndrome Foundation

[frrol]

I've met Missling, as has a colleague of mine who attended last year's GSM. He's a legitimate, experienced, hard working pharma finance guy. He has a tough task, because CNS therapies are notoriously difficult to develop. And he's trying to throw as much light on 2-73 as possible, but the facts are that we do not know how 2-73 really differs from other S1 agonists and don't know yet if it is truly effective clinically. He thinks so, but who doesn't loves their kids. Drugs fail. Robust trial results are proof, and he's working on them.

[Jonjones325]

I don’t remember that. I was sitting right next to you. Funny.